<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116034</url>
  </required_header>
  <id_info>
    <org_study_id>2019-CHF-005</org_study_id>
    <nct_id>NCT04116034</nct_id>
  </id_info>
  <brief_title>Alfapump Direct Sodium Removal (DSR) Feasibility Study</brief_title>
  <acronym>RED DESERT</acronym>
  <official_title>Alfapump DSR System in the Treatment of Diuretic Resistant Heart Failure Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sequana Medical N.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sequana Medical N.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in Human feasibility and sfafety study of the alfapump DSR system in the treatment of&#xD;
      Heart failure subects resistant to diuretic therapy. Up to 10 subjects will be enrolled in up&#xD;
      to 3 centres in Belgium and Georgia and will be iplanted with the alfapump DSR system.&#xD;
      Subjects will undergo DSR titration during a 2 week hospitalisation period, and will continue&#xD;
      titrated DSR therapy as outpatients for 4 more weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 10 subjects diagnosed with stable chronic heart failure (CHF) on high oral diuretic&#xD;
      dose and an MDRD eGFR &gt; 30ml/min/1.73m2 will undergo subcutaneous implantation of the&#xD;
      alfapump DSR system (Day-13) and portacath system and participate in a 6 week interventional&#xD;
      study. Prior to an inpatient study period, the subject will undergo a 40mg IV furosemide (or&#xD;
      1 mg IV bumetanide) diuretic challenge with timed biospecimen collection. On day 14&#xD;
      post-implant (Day 0), the subject will be admitted for a 14-day period in which diuretics&#xD;
      will be withheld and subjects will be on a strict low-sodium (3g/day) diet with strict&#xD;
      intake/output and all urine collected and samples saved for analysis. During the first 7 days&#xD;
      (Day 0 - 6) subjects will be treated with 1000ml of DSR Infusate Monday, Wednesday, Friday&#xD;
      administered to the peritoneal cavity through the subcutaneous peritoneal catheter. The&#xD;
      infusate will remain in the peritoneal cavity for a 2 hour dwell time, then all fluid will be&#xD;
      removed from the peritoneal cavity to the urinary bladder using the alfapump DSR system over&#xD;
      the subsequent 8 hours. On day 7, subjects will be transitioned to a moderate to high salt&#xD;
      diet given as the same low-sodium (3g/day) diet with supplementation with sodium chloride&#xD;
      tablets (2g/day) (5g/day total sodium), as this will likely represent their typical home&#xD;
      sodium intake. During this time, the optimal treatment protocol (frequency of administration&#xD;
      and volume of DSR infusate administered) for individual subjects based on daily sodium&#xD;
      balance, weight changes, and blood pressure will be created and tested over the next seven&#xD;
      days in hospital (Day 7 - 13). Following the inpatient period, a second diuretic challenge&#xD;
      will be conducted. Over the subsequent 28 days, diuretics will continue to be withheld with&#xD;
      preferential maintenance of euvolemia through DSR and subjects will come into the clinic&#xD;
      based on their tailored therapy schedule and undergo supervised DSR infusate administration.&#xD;
      Addition of diuretic treatment will only be allowed if maximal DSR therapy has been&#xD;
      instituted (DSR 7 days per week (i.e., including weekends) at 1.5L per session with dwell&#xD;
      time of 4 hours) and/or holding diuretics until additional DSR can be utilized would&#xD;
      represent a risk to the subject, as described in the CIP diuretic algorithm.&#xD;
&#xD;
      After the completion of the study period, the alfapump DSR therapy is halted and the subject&#xD;
      undergoes a third diuretic challenge to quantify diuretic response. At this point oral&#xD;
      diuretic therapy will be resumed. At the end of the study the alfapump can remain implanted&#xD;
      and set to 'dormant' state after discussion and agreement between subject and investigator,&#xD;
      and if there are no clinical, ethical or other reasons indicating explanation of the&#xD;
      alfapump. Alternatively, the subject may elect to enroll into a low intensity follow-on&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 26, 2019</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">April 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>up to 10 subjects will be enrolled to evaluate feasibility and safety of thealfapump DSR system</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety in-hospital - Device related</measure>
    <time_frame>Through Day 14 of treatment period</time_frame>
    <description>Rate of device related serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety in-hospital - therapy related</measure>
    <time_frame>Through Day 14 of treatment period</time_frame>
    <description>Rate of therapy related serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety in-hospital - procedure related</measure>
    <time_frame>Through Day 14 of treatment period</time_frame>
    <description>Rate of procedure related serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety during treatment period - device related</measure>
    <time_frame>through Day 42 of treatment period</time_frame>
    <description>Rate of device related serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety during treatment period - procedure related</measure>
    <time_frame>through Day 42 of treatment period</time_frame>
    <description>Rate of procedure serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety during treatment period - therapy related</measure>
    <time_frame>through Day 42 of treatment period</time_frame>
    <description>Rate of therapy related serious adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibiity endpoint sodium balance in-hospital</measure>
    <time_frame>through Day 14 of DSR therapy</time_frame>
    <description>Number of patients with neutral sodium balance (sodium intake equal to sodium output) in the absence of diuretic therapy during hospitalization period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility endpoint sodium balance during treatment period</measure>
    <time_frame>Through Day 42 of DSR Therapy</time_frame>
    <description>Number of patients with neutral sodium balance (sodium intake equal to sodium output) in the absence of diuretic therapy in a titrated schedule during treatment period</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Bioimpedance</measure>
    <time_frame>At baseline, day 7, 14, and 42</time_frame>
    <description>Change in bioimpedance from baseline through treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoconcentration markers</measure>
    <time_frame>At baseline, day 7, 14, and 42</time_frame>
    <description>Change in hemoglobin versus hematocrit ratio from baseline through treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>N-Terminal Prohormone of Brain Natriuretic Peptide (nt-ProBNP)</measure>
    <time_frame>At baseline, day 7, 14, and 42</time_frame>
    <description>Change in nt-proBNP from basline through treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>At baseline, day 7, 14, and 42</time_frame>
    <description>Change in Weight from baseline through treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycolated Hemoglobine (HbA1c)</measure>
    <time_frame>At baseline, day 7, 14, and 42</time_frame>
    <description>Changes in HBA1c from baseline through treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Sodium balance</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Daily sodium balance</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluid balance</measure>
    <time_frame>Up to day 42</time_frame>
    <description>Daily fluid balance</description>
  </other_outcome>
  <other_outcome>
    <measure>6-hour diuretic response</measure>
    <time_frame>At baseline, day 14, day 42</time_frame>
    <description>Change in response to 6 hour diuretic challenge from baseline through treatment</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Cardiorenal Syndrome</condition>
  <condition>Volume Overload</condition>
  <condition>Sodium Excess</condition>
  <condition>Sodium Disorder</condition>
  <arm_group>
    <arm_group_label>DSR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 10 subjects will be treated with alfapump DSR system for a total treatment period of 59 days post-implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>alfapump DSR system</intervention_name>
    <description>Infusion of sodium free Dextrose 10% into peritoneal cavity to remove sodium and fluid using principles of peritoneal dialysis, sodium and ultrafiltrate will be evacuated to the bladder by the alfapump</description>
    <arm_group_label>DSR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects &gt; 18 years of age&#xD;
&#xD;
          2. eGFR &gt; 30ml/min/14.73m2&#xD;
&#xD;
          3. Diagnosis of heart failure with one of the following: a. nt-proBNP &gt; 400 pg/ml (or BNP&#xD;
             &gt; 100 pg/mp) and oral diuretic dose ≥ 80mg furosemide (or 20mg torsemide or 1mg&#xD;
             bumetanide) OR b. Oral diuretic dose ≥ 120mg furosemide (or 30 mg torsemide or 1.5 mg&#xD;
             bumetanide)&#xD;
&#xD;
          4. Stable diuretic dose for 30 days&#xD;
&#xD;
          5. Systolic blood pressure ≥ 100 mmHg&#xD;
&#xD;
          6. Determined by treating provider to be at optimal volume status&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Candidates for participation will be ineligible for the study if any of the following&#xD;
        exclusion criteria apply:&#xD;
&#xD;
          1. Proteinuria &gt; 1g/day&#xD;
&#xD;
          2. BMI &gt; 40&#xD;
&#xD;
          3. History of abdominal surgery or peritonitis&#xD;
&#xD;
          4. Anemia with hemoglobin &lt; 8g/dL&#xD;
&#xD;
          5. Serum sodium &lt; 135 mEq/L&#xD;
&#xD;
          6. Severe hyperkalemia or baseline plasma potassium &gt; 4.5 mEq/L&#xD;
&#xD;
          7. Significant other organ disease or comorbidities&#xD;
&#xD;
          8. Hospitalization within 90 days&#xD;
&#xD;
          9. Cirrhosis&#xD;
&#xD;
         10. Hemodynamically significant stenotic valvular disease&#xD;
&#xD;
         11. Active or recurrent urinary tract infection or history of renal transplant&#xD;
&#xD;
         12. History of significant bladder dysfunction expected to interfere with ability of&#xD;
             subject to tolerate DSR pumping into bladder&#xD;
&#xD;
         13. Uncontrolled diabetes with frequent hyperglycemia or Type 1 diabetes&#xD;
&#xD;
         14. Subject is currently participating in another clinical trial&#xD;
&#xD;
         15. Subject is unable to comply with all required study follow-up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jozef Bartunek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Onze Lieve Vrouw Hospital Aalst, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart &amp; Vascular Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Georgia</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardio-Renal Syndrome</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD data will be shared with other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

